Differential Effects of Prednisolone and Azathioprine on the Development of Human Cytomegalovirus Replication Post Liver Transplantation
- 15 September 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 84 (5) , 605-610
- https://doi.org/10.1097/01.tp.0000280555.08651.11
Abstract
We sought to investigate the impact of different immunosuppressive regimens on human cytomegalovirus (HCMV) incidence and replication dynamics in a cohort of 256 patients after liver transplantation. A time-updated approach was used to determine the risk of developing HCMV replication (>200 genomes/mL blood) within the first 100 days after liver transplantation according to the immunosuppressive regimen being received at specific time points. In patients receiving tacrolimus, the addition of prednisolone was associated with a significant increased risk of HCMV replication both at baseline (relative rate of infection [RRI]=4.34; P=0.0001) and in a time-updated analysis (RRI=4.68; P=0.0001). However, the addition of azathioprine substantially reduced the risk of HCMV replication to that observed with tacrolimus alone. As expected donor/recipient HCMV serostatus was also a risk factor for viraemia. Multivariable models showed that the tacrolimus plus prednisolone regimen and donor/recipient serostatus were independent risk factors for HCMV replication. Viral replication dynamics showed that the duration of HCMV viraemia, the peak viral load, and the growth rate of HCMV were greatest in patients receiving tacrolimus plus prednisolone although these differences did not reach statistical significance. The combination of prednisolone plus tacrolimus as baseline immunosuppression after liver transplantation is associated with a high risk of HCMV replication. This effect can be negated by the addition of azathioprine.Keywords
This publication has 28 references indexed in Scilit:
- Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjectsThe Journal of Experimental Medicine, 2005
- Reduction of CMV Disease with Steroid-Free Immunosuppresssion in Simultaneous Pancreas–Kidney Transplant RecipientsAmerican Journal of Transplantation, 2005
- Kinetics of Cytomegalovirus Load Decrease in Solid‐Organ Transplant Recipients after Preemptive Therapy with ValganciclovirThe Journal of Infectious Diseases, 2005
- Cellular Immune Responses to Cytomegalovirus in Renal Transplant RecipientsAmerican Journal of Transplantation, 2004
- Cytomegalovirus (CMV)-Specific cellular immune responsesHuman Immunology, 2004
- Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2004
- Human Cytomegalovirus (HCMV) Replication Dynamics in HCMV‐Naive and ‐Experienced Immunocompromised HostsThe Journal of Infectious Diseases, 2002
- Preemptive Use of Oral Ganciclovir to Prevent Cytomegalovirus Infection in Liver Transplant Patients: A Randomized, Placebo‐Controlled TrialThe Journal of Infectious Diseases, 2002
- CD8+Cytotoxic Lymphocyte Responses against Cytomegalovirus after Liver Transplantation: Correlation with Time from Transplant to Receipt of TacrolimusThe Journal of Infectious Diseases, 2001
- CYTOMEGALOVIRUS INFECTION AND DONOR/RECIPIENT HLA ANTIGENS: INTERDEPENDENT CO-FACTORS IN PATHOGENESIS OF VANISHING BILEDUCT SYNDROME AFTER LIVER TRANSPLANTATIONThe Lancet, 1988